Johnson & Johnson vaccine was 72 percent effective in U.S. trial

Johnson & Johnson’s coronavirus vaccine was 72 Percent effective in early data from a late-stage US study, the company said Friday. Against a virus variant first identified in South Africa, however, the effectiveness of the vaccine fell to 52 percent.

The highly anticipated vaccine has several logistical advantages over approved vaccinations from Moderna and Pfizer: It is given as a single dose and can be stored in refrigerators instead of freezers.

The United States has bought 100 million cans of the Johnson & Johnson vaccine with the option to purchase an additional 200 million doses.

Leave a Comment